Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Anaphylaxis; Dyspnoea; Redness around the neck/Redness with thigh; itching/itching with thigh; cough; Nausea; Respiratory rate was 32; Pulse rate was 112; blood pressure was 58; This is a spontaneous report from a contactable physician received from the Regulatory Agency. Regulatory authority report number is v21111866. A 49-year-old female patient received the first dose of BNT162B2 (COMIRNATY, Solution for injection, Lot number FA4597, Expiration date 31Aug2021) via an unspecified route of administration on 04Jun2021 at 16:00 at age of 49 years old as single dose for COVID-19 immunization. Medical history included shrimp allergy. Concomitant medications were unknown. The patient previously received lidocaine (XYLOCAINE) and experienced drug allergy. The course of the event was as follows: On 04Jun2021 at 16:05 (5 minutes after the vaccination, as reported), the patient experienced Dyspnoea, Redness around the neck, Itching, Cough, Nausea, Redness with thigh and itching. And Pulse rate was 112, respiratory rate was 32, blood pressure was 58, SPO2 was 98 to 99 %.The patient began to inhale oxygen, BOSMIN 0.3mg, Atarax-P 25 mg Intramuscular, Meptin air 2 push was enforced. Secure the route and 100 ml of saline and Solu-Medrol 125mg was administration. The patient was hospitalized. This report meet the criteria of Anaphylaxis. The outcome of the events were unknown. The reporting physician classified the event as serious (Hospitalized) and assessed that the event was related to BNT162B2. There was no other possible cause of the event such as any other diseases.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166